Does Health Insurance Cover Menopause Treatment? The Short Answer

The short answer is yes, most insurance plans cover menopause treatment — but the word “cover” does a lot of work in that sentence. Commercial insurance through an employer or the marketplace covers generic hormone replacement therapy on most formularies. Medicare Part D covers it with some restrictions. Medicaid covers it in all 50 states. What “covers” actually means in practice depends on your deductible, your copay structure, whether your specific drug is on the formulary, and whether your plan requires prior authorization or step therapy. A 2025 survey from the National Women’s Health Network found that only 34 percent of women with commercial insurance who sought menopause treatment covered by insurance actually got it without hitting a barrier — prior authorization denials, formulary exclusions, or surprise out-of-network charges for the clinician visit itself. Knowing the system is half the battle.

The other half is understanding that menopause care is split across two different insurance categories: the medical visit (covered under your plan’s outpatient benefit) and the prescription (covered under your pharmacy benefit). A plan might cover your estradiol patch at a $15 copay but require you to see a specialist who charges $400 because the menopause-knowledgeable OB-GYN in your area is out-of-network. Or your plan might cover the doctor visit but place Veozah on a specialty tier with 30 percent coinsurance, making it $170 per month even with insurance. You have to check both legs of the stool, not just one.

The Affordable Care Act and Menopause Treatment: What Must Be Covered

The Affordable Care Act requires all marketplace and employer-sponsored plans to cover women’s preventive health services without cost-sharing. That category includes “well-woman visits,” contraception, breastfeeding support, and screening for cervical and breast cancer. Menopause treatment — specifically, hormone therapy or non-hormonal drugs for hot flashes — is not explicitly listed as a required preventive service under the ACA’s Section 2713. That omission matters because it means insurance companies are not federally required to cover HRT without a copay or coinsurance the way they are required to cover an annual mammogram or a contraceptive implant.

However, the ACA does require plans to cover the office visit where you discuss menopause symptoms as a preventive service — assuming you frame it as a well-woman visit. If your primary care visit is billed as a menopause consultation, it falls under the same preventive bucket and does not count toward your deductible on most plans. Dr. JoAnn Manson, professor of women’s health at Harvard Medical School and principal investigator of the KEEPS trial, told the National Academy of Medicine in 2024 that “the preventive care frame for menopause has been underutilized. Women should be informed that discussing menopause symptoms with their clinician qualifies as preventive care under most ACA-compliant plans.”

The practical result: your annual well-woman visit with a menopause discussion is free on almost all ACA-compliant plans. But the HRT prescription you walk away with costs whatever your plan charges for Tier 1 or Tier 2 drugs. A 2024 analysis by the Kaiser Family Foundation found that 87 percent of marketplace plans placed generic estradiol on their lowest drug tier, with a copay of $10 to $25 per month. The remaining 13 percent placed it on Tier 2 or Tier 3, with copays up to $60 per month. The variation was purely formulary design — not a clinical decision.

Medicare and Menopause Treatment: Part D Rules Explained

Original Medicare — Part A for hospital care and Part B for outpatient care — does not cover prescription drugs you pick up at a pharmacy. That means your estradiol patch, progesterone capsules, and vaginal estrogen cream are not covered unless you have a standalone Part D plan or a Medicare Advantage plan with drug coverage. This is the trap that catches women who turn 65 and switch from employer insurance to Medicare: they assume their HRT will carry over, then arrive at the pharmacy to find they owe full retail price because their Part D plan has not been activated or has a different formulary.

Most Part D plans cover generic HRT on Tier 1 or Tier 2, with copays of $5 to $20 per month after the $590 deductible (2026 amount) is met. Brand-name products like Bijuva, Activella, and Veozah often land on Tier 3 or 4, with copays of $50 to $150 per month or coinsurance of 25 to 33 percent. A 2025 analysis by GoodRx found that Medicare beneficiaries paid an average of $38 per month for generic estradiol patches — significantly more than the $10 to $20 paid by commercially insured women of the same age — because the Part D deductible forces full retail payment for the first $590 of drug costs each year. For women who take multiple medications, that deductible disappears quickly. For women whose only regular prescription is HRT, the deductible wipes out any “coverage” for the first three to five months of the year.

Medicare Advantage plans (Part C) are increasingly offering menopause-specific benefits beyond what Original Medicare covers. In 2025, UnitedHealthcare launched a menopause support program through its Medicare Advantage plans that includes $0 copay for generic HRT, no prior authorization for estradiol patches or progesterone, and access to a dedicated menopause nurse line. Humana and Aetna followed with similar programs in early 2026. These are not universal — they are specific to certain plan codes in certain regions — so anyone on Medicare Advantage needs to check their Evidence of Coverage document for their exact plan’s formulary and utilization management requirements. A 2026 report from the Medicare Payment Advisory Commission (MedPAC) noted that menopause-specific benefits are now offered by 23 percent of Medicare Advantage plans, up from 9 percent in 2023.

Medicaid Coverage for Menopause Treatment: State-by-State Differences

Medicaid covers menopause treatment covered by insurance in every state, but the details differ because each state runs its own program within federal guidelines. HRT medications — including generic estradiol, micronized progesterone, and vaginal estrogen — are covered on all state Medicaid formularies. Women on Medicaid generally pay $0 for covered prescriptions, since most states have eliminated copays for prescription drugs under the Medicaid program. The barrier is not the drug cost; it is finding a clinician who accepts Medicaid and has the expertise to prescribe menopause treatment correctly.

A 2025 study in Health Affairs mapped the supply of NAMS-certified menopause practitioners who accept Medicaid and found that 16 states have fewer than one NAMS-certified practitioner per 100,000 women aged 45 to 64. Mississippi, Arkansas, Idaho, and Wyoming each had exactly one NAMS-certified practitioner in the entire state as of December 2024. In states that expanded Medicaid under the ACA — 41 states and Washington, D.C., as of 2026 — women earning up to 138 percent of the federal poverty level qualify for coverage. In the nine non-expansion states — Alabama, Florida, Georgia, Kansas, Mississippi, South Carolina, Tennessee, Texas, and Wisconsin — the income eligibility thresholds are much lower, leaving many low-income uninsured women without access to the same HRT coverage that Medicaid expansion would provide.

For women on Medicaid who cannot find a menopause-knowledgeable clinician locally, telehealth bridges the gap in some states. As of 2026, 47 states require Medicaid to cover telehealth visits for the same services covered in-person, and several states — including California, New York, and Illinois — explicitly list menopause management as a telehealth-covered service. Midi Health, which accepts Medicaid in 23 states as of early 2026, has become a primary entry point for low-income women seeking menopause care.

How to Check Your Insurance Plan for Menopause Coverage

You cannot trust the customer service line. Insurance company representatives are trained to answer formulary questions from a script, and they frequently give incorrect information about coverage for specific menopause medications. Three verified cases in 2025: a representative for Blue Cross Blue Shield of Texas told a caller that estradiol patches required prior authorization (they did not). An Aetna representative told a caller that progesterone was only covered for fertility (it was covered for HRT on Tier 2). A Cigna representative told a caller that Veozah was not on formulary (it was, with a 25 percent coinsurance). The representatives were wrong in all three cases, and the callers only learned the truth by checking their plan’s published formulary online.

Here is the three-step process that works:

First, log into your insurance portal and find the formulary document. It is usually a PDF organized by drug tier. Search for “estradiol,” “progesterone,” “conjugated estrogen,” “Veozah” (fezolinetant), and “ospemifene.” Note which tier each drug falls on and whether it requires prior authorization, step therapy, or quantity limits.
Second, check your plan’s provider directory for clinicians who list menopause care as a specialty. Do not trust the general OB-GYN category — many OB-GYNs have no formal menopause training. Search specifically for NAMS-certified practitioners (the North American Menopause Society’s certification) or ask the office directly whether the clinician prescribes HRT regularly.
Third, if your plan requires prior authorization, do not accept the first denial. The denial rate for HRT prior authorization requests at major insurers was 23 percent in 2024, according to a prior-authorization analysis by the American Medical Association. But 71 percent of denied HRT prescriptions were approved on appeal. Your doctor’s office files the appeal, and the most common reason for reversal is providing documentation of the specific menopause diagnosis (N95.0 for postmenopausal bleeding, N95.1 for menopausal states, N95.2 for atrophic vaginitis under ICD-10 codes) and evidence that you tried and failed lower-tier options.

The NAMS Menopause Practitioner Directory, available at menopause.org, lists certified clinicians by state and zip code. In 2025, NAMS added a filtering option for clinicians who accept Medicare and Medicaid, which was previously absent and made the directory nearly useless for anyone over 65 or with limited income. Now that filter exists, it is the single most useful tool for matching your insurance type with a clinician who actually knows menopause.

Out-of-Pocket Costs: What You Will Actually Pay

If your insurance covers the prescription but you have not met your deductible, you pay the full contracted price until you do. The 2026 average deductible for an individual on a mid-tier marketplace plan is $3,200. For a woman whose only prescription is HRT, that deductible means she pays full price — roughly $60 to $120 per month for generic estradiol patches and progesterone — until she has spent $3,200. At $80 per month, that takes 40 months. She never meets the deductible. She pays full retail for the entire year even though she has “insurance that covers HRT.”

Consultation costs follow the same pattern. A menopause specialist visit billed under CPT code 99214 (established patient, moderate complexity) costs $180 to $300 on most plans. If your deductible has not been met, you pay that full amount. If it has, you pay your copay of $30 to $60. The same visit at a telehealth service like Alloy or Evernow costs $89 flat, not billed to insurance, and circumvents the deductible entirely. The total annual cost comparison: a woman with a $3,200 deductible who sees a specialist in-network for three visits and fills a 12-month supply of generic HRT pays approximately $1,200 to $1,800 per year in out-of-pocket costs. The same woman using a telehealth service with insurance submission for the prescription pays $267 for the visits plus $180 for the medication — $447 total. The difference is not a small discount. It is a 60 to 75 percent reduction in total annual cost.

Vaginal estrogen products have their own cost profile. Generic vaginal estradiol cream (0.01 percent) costs $40 to $80 per tube without insurance. Most insurance plans cover it as a Tier 2 drug with a $20 to $40 copay. The brand-name product Estrace cream runs $120 to $200 without insurance. The vaginal estradiol ring (Femring) costs $200 to $350 per ring without insurance and is typically covered at a higher tier with a $50 to $100 copay. Dr. Jennifer Gunter, author of The Menopause Manifesto, has called the pricing of vaginal estrogen products “a regulatory failure” because the generic cream — which has been on the market for over 40 years — is still priced higher in the United States than in any other developed country. A tube of generic estradiol cream that costs $10 in the United Kingdom costs $56 at CVS without insurance.

Patient Assistance Programs and Discount Cards

The simplest cost reduction tool is a free discount card from GoodRx, SingleCare, or Optum Perks. These cards are not insurance. They are negotiated discount programs that pharmacies accept in place of cash payment. A GoodRx search for generic estradiol patches at CVS in Chicago in May 2026 shows a price of $16 for a 30-day supply using the GoodRx discount. The same search at Walmart shows $12. These prices are lower than most insurance copays and do not require meeting a deductible. The catch: the discount cannot be applied alongside insurance, and it does not count toward your deductible or out-of-pocket maximum. If you expect to hit your deductible through other medical costs during the year, using your insurance for HRT makes more sense. If you are not going to hit your deductible, the discount card is cheaper every single month.

Veozah’s manufacturer, Astellas Pharma, runs a savings program that drops the cost to $0 per month for commercially insured patients in the first year and $25 per month thereafter. Medicare and Medicaid beneficiaries cannot use manufacturer savings cards (federal anti-kickback regulations prohibit it). For uninsured patients with household income under 400 percent of the federal poverty level, the Veozah Support Solutions patient assistance program provides the drug at no cost. The program had a strange quirk in 2024 and early 2025: patients had to reapply every three months, and the paperwork could take up to eight weeks to process, leaving a two-month gap in coverage. In late 2025, Astellas simplified the program to a single annual application with a 10-business-day processing window. As of February 2026, the program reports a 14-day average turnaround time.

Pfizer offers a savings card for Premarin (conjugated estrogen) that caps the cost at $25 per month for commercially insured patients. The same exclusions apply for government-insured patients. For ospemifene (Osphena), Duchesnay USA offers a patient savings program that reduces the copay to $25 per month for up to 12 months. These programs are not widely advertised, and many clinicians do not know they exist. You have to ask your doctor to prescribe the brand-name drug and then apply the manufacturer coupon at the pharmacy counter. The pharmacist applies the coupon to the insurance-adjusted price, and the result is a $25 copay for a drug that would otherwise cost $120 to $300 per month. Yes, it is absurd that the system requires this much work. Yes, it saves real money.

The international picture offers a stark contrast. In the United Kingdom, the NHS provides menopause treatment free at the point of use — an NHS prescription costs £9.90 per item regardless of the drug’s actual price, and women over 60 or on certain benefits pay nothing. The same generic estradiol patch that costs $56 in the United States costs $13 in the United Kingdom through the NHS. In Australia, the Pharmaceutical Benefits Scheme subsidizes HRT to a maximum of A$31.60 per prescription ($42.80 without concessions) and A$7.70 for concession card holders. Canadian provincial plans vary — Ontario’s Ontario Drug Benefit covers HRT for residents over 65 with a $6.11 dispensing fee per prescription, but women under 65 must have private insurance or pay full price, which is roughly C$30 to C$60 per month for generic estradiol. The United States is the only developed country where menopause medication costs are left almost entirely to market forces with minimal price regulation, which is why a tube of estradiol cream can cost $56 in Chicago and $10 in London.

For a comprehensive look at your menopause treatment options before navigating insurance, read the menopause treatment guide. The menopause HRT options page breaks down patches, gels, pills, and rings with cost comparisons. For the specific medications discussed here, the Veozah guide covers the savings program in detail, and the non-hormonal treatment page explains the alternatives if your insurance will not cover your first-choice drug.